Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Cash from Operations (2016 - 2025)

Assembly Biosciences (ASMB) has 11 years of Cash from Operations data on record, last reported at 15133000.0 in Q3 2025.

  • For Q3 2025, Cash from Operations rose 0.73% year-over-year to 15133000.0; the TTM value through Sep 2025 reached 55737000.0, down 343.0%, while the annual FY2024 figure was 51117000.0, 324.76% down from the prior year.
  • Cash from Operations reached 15133000.0 in Q3 2025 per ASMB's latest filing, up from 16758000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 73647000.0 in Q4 2023 and bottomed at 33344000.0 in Q1 2021.
  • Average Cash from Operations over 5 years is 13766473.68, with a median of 18364000.0 recorded in 2024.
  • Peak YoY movement for Cash from Operations: crashed 277.36% in 2021, then skyrocketed 482.5% in 2023.
  • A 5-year view of Cash from Operations shows it stood at 19362000.0 in 2021, then grew by 0.56% to 19254000.0 in 2022, then surged by 482.5% to 73647000.0 in 2023, then plummeted by 100.55% to 407000.0 in 2024, then plummeted by 3618.18% to 15133000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 15133000.0 in Q3 2025, 16758000.0 in Q2 2025, and 23439000.0 in Q1 2025.